GSK's near-term litigation leverage has been reduced — the denial gives defendants wider latitude to depose central inventor witnesses, which could strengthen their invalidity and non-infringement defenses. GSK must now prepare for more extensive depositions ahead of the July 29 discovery deadline. Monitor for any settlement signals or claim construction rulings as the case progresses toward trial.
Price Chart
Executive Summary
GSK was denied a motion to limit third-party deposition hours in its patent infringement cases against Pfizer/BioNTech and Moderna. A Special Master ruled that GSK failed to show good cause to restrict each defendant group to a combined 10 hours of depositions for key inventor witnesses, upholding the default seven-hour-per-party deposition standard. The decision is a procedural setback but not a merits ruling — it increases GSK's litigation burden and costs but does not affect the substantive patent claims.
Court Ruling Details
Key Facts
- GSK sued Pfizer/BioNTech and Moderna for patent infringement relating to mRNA vaccine technology across three consolidated actions in Delaware.
- GSK sought to limit the defendants to a combined 10 hours of deposition time for key inventors Dr. Andrew Geall and Dr. Christian Mandl.
- The Special Master denied GSK's motion, finding no good cause to override the default seven-hour deposition per party under Rule 30(d)(1).
- Dr. Geall is named inventor on all eight patents asserted against Pfizer/BioNTech and is sole inventor on seven of those.
- Fact discovery closes July 29, 2026 across all three actions.
- The ruling allows each defendant group (Pfizer/BioNTech and Moderna) up to 7 hours per inventor witness, totaling up to 14 hours per inventor rather than GSK's proposed 10-hour combined cap.
Financial Impact
No immediate financial damages or monetary ruling. The decision increases GSK's litigation costs by allowing broader depositions, potentially extending the discovery phase and raising legal expenses. No specific dollar amount stated in the ruling.
Risk Factors
- Depositions of Dr. Geall and Dr. Mandl for up to 14 hours each could expose weaknesses in GSK's patent positions.
- Discovery costs will be higher than anticipated given the denial of coordinated, shorter depositions.
- GSK has lost procedural ground on a scheduling issue, which may signal the court's attitude toward future GSK motions.
- No damages or injunction were awarded — this is a procedural ruling only, limiting the potential market reaction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-3rrqn0ol-GSK |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $50.01 $50.22 | ▲ +0.42% | ▼ −0.40% | $47.03 (−5.96%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 11, 2026 21d ago | 6-K | $48.13 $50.22 | ▲ +4.34% | ▲ +4.56% | $47.03 (−2.29%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Aug 26, 2026 5w ago | 6-K | $51.43 $50.44 | ▼ −1.92% | ▼ −1.80% | $47.03 (−8.56%) |
Aug 24, 2026 5w ago | 6-K | $51.78 $50.25 | ▼ −2.95% | ▼ −3.42% | $47.03 (−9.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access